Your browser doesn't support javascript.
Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond.
Beecker, J; Papp, K A; Dutz, J; Vender, R B; Gniadecki, R; Cooper, C; Gisondi, P; Gooderham, M; Hong, C H; Kirchhof, M G; Lynde, C W; Maari, C; Poulin, Y; Puig, L.
  • Beecker J; University of Ottawa, Ottawa, ON, Canada.
  • Papp KA; Division of Dermatology, The Ottawa Hospital, Ottawa, ON, Canada.
  • Dutz J; Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Vender RB; Probity Medical Research Inc., Waterloo, ON, Canada.
  • Gniadecki R; Probity Medical Research Inc., Waterloo, ON, Canada.
  • Cooper C; K Papp Clinical Research, Waterloo, ON, Canada.
  • Gisondi P; Skin Care Center, Vancouver, BC, Canada.
  • Gooderham M; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.
  • Hong CH; Skin Science, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
  • Kirchhof MG; Dermatrials Research Inc., Hamilton, ON, Canada.
  • Lynde CW; Department of Medicine, McMaster University, Hamilton, ON, Canada.
  • Maari C; Probity Medical Research Inc., Waterloo, ON, Canada.
  • Poulin Y; Division of Dermatology, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
  • Puig L; University of Ottawa, Ottawa, ON, Canada.
J Eur Acad Dermatol Venereol ; 35(4): 797-806, 2021 Apr.
Article in English | MEDLINE | ID: covidwho-1060905
ABSTRACT
Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2, a novel RNA virus that was declared a global pandemic on 11 March 2020. The efficiency of infection with SARS-CoV-2 is reflected by its rapid global spread. The SARS-CoV-2 pandemic has implications for patients with inflammatory skin diseases on systemic immunotherapy who may be at increased risk of infection or more severe infection. This position paper is a focused examination of current evidence considering the mechanisms of action of immunotherapeutic drugs in relation to immune response to SARS-CoV-2. We aim to provide practical guidance for dermatologists managing patients with inflammatory skin conditions on systemic therapies during the current pandemic and beyond. Considering the limited and rapidly evolving evidence, mechanisms of action of therapies, and current knowledge of SARS-CoV-2 infection, we propose that systemic immunotherapy can be continued, with special considerations for at risk patients or those presenting with symptoms.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Dermatitis / COVID-19 / Immunotherapy Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: J Eur Acad Dermatol Venereol Journal subject: Dermatology / Sexually Transmitted Diseases Year: 2021 Document Type: Article Affiliation country: Jdv.17075

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Dermatitis / COVID-19 / Immunotherapy Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: J Eur Acad Dermatol Venereol Journal subject: Dermatology / Sexually Transmitted Diseases Year: 2021 Document Type: Article Affiliation country: Jdv.17075